CORC  > 复旦大学上海医学院
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Qin, Shukui; Bai, Yuxian; Lim, Ho Yeong; Thongprasert, Sumitra; Chao, Yee; Fan, Jia; Yang, Tsai-Shen; Bhudhisawasdi, Vajarabhongsa; Kang, Won Ki; Zhou, Yu
刊名JOURNAL OF CLINICAL ONCOLOGY
2013
卷号31期号:28
ISSN号0732-183X
URL标识查看原文
语种英语
内容类型期刊论文
URI标识http://www.corc.org.cn/handle/1471x/4901485
专题复旦大学上海医学院
推荐引用方式
GB/T 7714
Qin, Shukui,Bai, Yuxian,Lim, Ho Yeong,et al. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J]. JOURNAL OF CLINICAL ONCOLOGY,2013,31(28).
APA Qin, Shukui.,Bai, Yuxian.,Lim, Ho Yeong.,Thongprasert, Sumitra.,Chao, Yee.,...&Sun, Yan.(2013).Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia.JOURNAL OF CLINICAL ONCOLOGY,31(28).
MLA Qin, Shukui,et al."Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia".JOURNAL OF CLINICAL ONCOLOGY 31.28(2013).
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace